


# **COVID-19 Vaccination Progress: United States**

**Christine Hahn, MD**  
**Idaho Division of Public Health**  
**CVAC 2/19/2021**




IDAHO DEPARTMENT OF  
**HEALTH & WELFARE**

# COVID-19 VACCINE ROLLOUT in the U.S.: DISTRIBUTION






Total Doses Administered Reported to the CDC by State/Territory and for Selected Federal Entities per 100,000



U.S. COVID-19 Vaccine Administration by Vaccine Type




# COVID-19 VACCINE ROLLOUT in the U.S.: ADMINISTRATION



Age Groups of People with 1 or More Doses Administered:

Download


Data from 40,268,009 people with 1 or more doses administered. Age was available for 37,208,253 (92%) people with 1 or more doses administered.



Race/Ethnicity of People with 1 or More Doses Administered:

Download


Data from 40,268,009 people with 1 or more doses administered. Race/Ethnicity was available for 21,989,501 (54.6%) people with 1 or more doses administered.




Sex of People with 1 or More Doses Administered:

Download

Data from 40,268,009 people with 1 or more doses administered. Sex was available for 36,584,273 (90.9%) people with 1 or more doses administered.



\*Sources: <https://covid.cdc.gov/covid-data-tracker/#vaccination-demographic> and <https://www.census.gov/quickfacts/fact/table/US/PST045219>



- FDA's Vaccines and Related Biological Products Advisory Committee will discuss the Johnson & Johnson (Janssen Biotech Inc.) vaccine on Feb 26<sup>th</sup> and will make a decision on authorization as soon as Feb 27<sup>th</sup>
- If authorized for use, CDC's Advisory Committee on Immunization Practices will meet Feb 28<sup>th</sup> to finalize recommendations on its use
  - Announced efficacy:
    - 66% against moderate to severe illness
    - 85% against severe disease (measured 28 days after vaccination)
    - 100% against hospitalization and death
  - Storage/Handling: refrigerator temperatures
  - Dose: single administration
  - 57% efficacy in South African cohort, but prevented hospitalization

